IRIS
ROTTOLI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.666
EU - Europa 14.461
AS - Asia 7.690
SA - Sud America 1.302
AF - Africa 332
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 16
Totale 41.504
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.354
GB - Regno Unito 3.128
CN - Cina 2.775
RU - Federazione Russa 2.618
SG - Singapore 2.141
IT - Italia 2.122
IE - Irlanda 1.891
UA - Ucraina 1.071
BR - Brasile 1.068
SE - Svezia 951
FR - Francia 927
VN - Vietnam 849
DE - Germania 784
HK - Hong Kong 631
FI - Finlandia 445
KR - Corea 345
IN - India 234
CA - Canada 191
BD - Bangladesh 146
ZA - Sudafrica 136
ES - Italia 111
TR - Turchia 105
AR - Argentina 89
JP - Giappone 89
PL - Polonia 75
NL - Olanda 71
MX - Messico 69
NG - Nigeria 69
IQ - Iraq 64
BE - Belgio 53
CZ - Repubblica Ceca 51
ID - Indonesia 34
PK - Pakistan 34
AT - Austria 32
AU - Australia 32
UZ - Uzbekistan 30
CO - Colombia 29
MA - Marocco 28
SA - Arabia Saudita 28
EC - Ecuador 27
CI - Costa d'Avorio 26
VE - Venezuela 22
IL - Israele 18
KE - Kenya 18
LT - Lituania 18
CL - Cile 17
PY - Paraguay 17
JM - Giamaica 16
AZ - Azerbaigian 15
PH - Filippine 15
IR - Iran 14
PT - Portogallo 14
RO - Romania 14
MY - Malesia 13
GR - Grecia 12
JO - Giordania 12
PE - Perù 12
TN - Tunisia 12
UY - Uruguay 12
KG - Kirghizistan 11
KZ - Kazakistan 11
AE - Emirati Arabi Uniti 10
EG - Egitto 10
EU - Europa 10
DZ - Algeria 9
CH - Svizzera 8
AL - Albania 7
BG - Bulgaria 7
BO - Bolivia 7
ET - Etiopia 7
NP - Nepal 7
CR - Costa Rica 6
EE - Estonia 6
HU - Ungheria 6
LU - Lussemburgo 6
CY - Cipro 5
DK - Danimarca 5
LB - Libano 5
LV - Lettonia 5
PA - Panama 5
XK - ???statistics.table.value.countryCode.XK??? 5
BB - Barbados 4
DO - Repubblica Dominicana 4
KW - Kuwait 4
LK - Sri Lanka 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
OM - Oman 4
PS - Palestinian Territory 4
RS - Serbia 4
TT - Trinidad e Tobago 4
AM - Armenia 3
AO - Angola 3
BY - Bielorussia 3
GE - Georgia 3
HN - Honduras 3
LA - Repubblica Popolare Democratica del Laos 3
PR - Porto Rico 3
QA - Qatar 3
SC - Seychelles 3
Totale 41.449
Salva come PNG Salva come JPEG
Città #
Southend 2.703
Dublin 1.881
Dallas 1.838
Fairfield 1.793
Singapore 1.231
Ashburn 1.188
Chandler 1.143
Houston 900
Jacksonville 862
Woodbridge 782
Santa Clara 727
Beijing 716
Moscow 710
Seattle 650
San Jose 628
Wilmington 601
Hong Kong 595
Cambridge 534
Ann Arbor 466
Siena 416
Princeton 361
Hefei 334
Seoul 308
The Dalles 278
Los Angeles 273
Nanjing 273
New York 246
Ho Chi Minh City 241
Helsinki 226
Lauterbourg 194
Hanoi 181
Council Bluffs 178
Munich 158
Menlo Park 151
Boardman 146
Buffalo 119
Dearborn 119
Johannesburg 119
Nanchang 117
Florence 111
San Diego 110
Dong Ket 95
Milan 94
São Paulo 89
London 85
Shanghai 85
San Mateo 84
Tokyo 73
Shenyang 71
Chicago 68
Abuja 67
Málaga 67
Rome 67
Chennai 66
Orem 66
Tianjin 60
Warsaw 59
Hebei 54
Changsha 53
Izmir 53
Düsseldorf 52
Turku 50
Columbus 49
Frankfurt am Main 49
Ottawa 49
Da Nang 48
Hangzhou 46
Montreal 46
Kunming 45
Guangzhou 41
Redondo Beach 40
Norwalk 39
Brussels 38
San Francisco 38
Fremont 37
Rio de Janeiro 37
Washington 37
Jiaxing 36
Toronto 36
Jinan 35
Brno 32
Haiphong 32
Catania 31
Denver 31
Nuremberg 31
Bengaluru 30
Brooklyn 30
Gavirate 30
Poplar 30
Amsterdam 29
Phoenix 29
Atlanta 28
Belo Horizonte 28
Manchester 27
Stockholm 27
Seongnam 26
Venezia 26
Zhengzhou 26
Abidjan 25
Boston 25
Totale 27.384
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.043
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 632
Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients 444
null 398
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 389
Cytokine modulators in the treatment of sarcoidosis 386
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 356
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 351
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 306
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 298
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 290
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 288
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 282
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 275
Exhaled nitric oxide in interstitial lung diseases 274
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 274
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 273
Asbestos exposure assessment by mineralogical analysis of bronchoalveolar lavage fluid 269
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 266
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 264
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 264
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 262
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 262
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 262
A difficult case: sarcoidosis with CNS involvement or sarcoidosis associated with multiple sclerosis? 261
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 261
Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model 259
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 255
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 250
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 250
Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients 246
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 246
Posttransplant solid organ malignancies in lung transplant recipients: A single-center experience and review of the literature 245
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 242
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 242
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 241
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 240
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 239
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 238
Diffuse panbronchiolitis in a patient with common variable immunodeficiency: a casual association or a pathogenetic correlation? 238
Serum amyloid A in patients with idiopathic pulmonary fibrosis 237
Bronchial stenosis following lung transplant: An innovative approach with a modified endobronchial emphysema valve 236
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 236
A functional proteomics approach to the comprehension of sarcoidosis 235
Chitotriosidase activity in patients with interstitial lung disesaes 231
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 227
Adaptive immune responses in primary cutaneous sarcoidosis 227
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 225
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 225
Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. 225
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 225
Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis 224
2D electrophoretic maps of BAL proteins in fibrosing lung diseases 224
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 219
Bone ultrasonography in glucocorticoid induced osteoporosis 219
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 217
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease 217
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 217
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 217
Abnormalities in calcium metabolism in sarcoidosis 216
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 216
Analysis of alveolar and peripheral CD45RO+ T-lymphocytes in sarcoidosis 215
Phenotypes of organ involvement in sarcoidosis 214
The analysis of tryptase in serum of sarcoidosis patients 212
Proteome analysis of bronchoalveolar lavage in lung diseases 212
Quality of life, anxiety and depression in Sarcoidosis 212
The pharmacological treatment of bronchiectasis 212
Assessment of cardiac involvement in sarcoidosis by echocardiography 211
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial 211
A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis. 211
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 209
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 207
Selection of Candidates for Lung Transplantation: The First Italian Consensus Statement 206
Chitotriosidase: a sensitive biomarker of sarcoidosis 206
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 205
Severe acute graft versus host disease after lung transplant: report of a case successfully treated with high dose corticosteroids 204
Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors 203
Serum analysis of coagulation factors in IPF and NSIP 203
Serum amyloid A: A potential biomarker of lung disorders 203
Postoperative acute kidney injury in lung transplant recipients 203
Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia 202
Extracorporeal Photopheresis in Lung Transplantation 202
Controversial role of RAGE in the pathogenesis of idiopathic pulmonary fibrosis 201
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension 201
Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study 200
Oxidative stress in the pathogenesis of diffuse lung diseases: a review 198
Doubts and certainness in diagnosis of pulmonary embolism in the elderly 198
Proteomic investigation of pulmonary sarcoidosis 198
Effects of calcitriol on IFN-gamma production by alveolar and peripheral lymphocytes of patients with sarcoidosis. 195
Sarcoidosis with upper respiratory tract involvement 194
Biomarkers in sarcoidosis: The contribution of system biology 194
Human Chitotriosidase: a sensitive biomarker of sarcoidosis 193
Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis 193
Concentrations of major elements and mercury in unstimulated human saliva 192
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 192
Gardening in greenhouses as a risk factor for silicosis. 190
IPF mortality in waiting list for lung transplantation 190
Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome 185
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 181
Urgent contralateral pneumonectomy after single lung transplantation for lymphangioleiomyomatosis. 180
Totale 24.914
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.094
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.094
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021300 0 0 0 0 0 0 0 0 0 0 0 300
2021/20222.687 202 387 146 219 127 71 122 124 119 291 311 568
2022/20233.957 295 344 489 589 389 774 78 318 394 95 127 65
2023/20242.810 136 59 231 100 102 760 968 71 17 73 52 241
2024/20255.380 147 296 559 289 689 279 159 271 383 260 624 1.424
2025/202612.399 1.053 1.713 1.536 1.499 2.424 551 1.535 369 421 702 320 276
Totale 41.979